Dopaminergic signalling in the striatum contributes to reinforcement of actions and motivational enhancement of motor vigour. Parkinson's disease leads to progressive dopaminergic denervation of the striatum, impairing the function of cortico-basal ganglia networks. While levodopa therapy alleviates basal ganglia dysfunction in Parkinson's disease, it often elicits involuntary movements, referr...

Dopaminergic signalling in the striatum contributes to reinforcement of actions and motivational enhancement of motor vigour. Parkinson’s disease leads to progressive dopaminergic denervation of the striatum, impairing the function of cortico-basal ganglia networks. While levodopa therapy alleviates basal ganglia dysfunction in Parkinson’s disease, it often elicits involuntary movements, referr...

Peak-dose dyskinesias are abnormal movements that usually occur 1 h after oral administration of levodopa, and often complicate chronic treatment of Parkinson's disease. We investigated by PET with [11C]raclopride whether Parkinson's disease progression modifies the striatal changes in synaptic dopamine levels induced by levodopa administration, and whether this modification, if present, could ...

Because an optimal time for beginning treatment with levodopa is not clarified so far, an aim of the study was to specify key risk factors for the development of motor fluctuations and dyskinesias and to study correlations between their manifestation and time for beginning treatment with levodopa. Forty patients (mean age 57,86+/-8,02 years; mean illness duration 6,38+/-3,2 years) with Parkinso...

In advanced stages of Parkinson's disease, serotonergic terminals take up L-DOPA and convert it to dopamine. Abnormally released dopamine may participate in the development of L-DOPA-induced dyskinesias. Simultaneous activation of 5-HT1A and 5-HT1B receptors effectively blocks L-DOPA-induced dyskinesias in animal models of dopamine depletion, justifying a clinical study with eltoprazine, a 5-HT...

SAN FRANCISCO and GENEVA, Feb. 10, 2015 (GLOBE NEWSWIRE) -Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the publication of the results of a Phase 2a stud...

143 may show a high T2 signal in the basal ganglia and caudate atrophy. Normal plasma lipid levels and lipoprotein electrophoresis help to distinguish this from abetalipoproteinaemia [4,6,8]. Proper evaluation of movement disorders in young people is necessary as there are important considerations regarding diagnosis, treatment and family counselling. Paroxysmal dyskinesias are commonly mistake...

We studied whether five sessions of 10 Hz repetitive transcranial magnetic stimulation (rTMS treatment) applied over the dorsolateral prefrontal cortex (DLPFC) or the primary motor cortex (MC) in advanced Parkinson's disease (PD) patients would have any effect on L-dopa-induced dyskinesias and cortical excitability. We aimed at a randomised, controlled study. Single-pulse transcranial magnetic ...

SAN FRANCISCO and GENEVA, Feb. 10, 2015 (GLOBE NEWSWIRE) -Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the publication of the results of a Phase 2a stud...